Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners

BD Biosci

Other names: Becton, Dickinson and Company | BD Biosciences | Tripath Oncology | TriPath Oncology, Inc. | TriPath Oncology Inc. | TriPath Oncology Inc | TriPath Imaging | TriPath Oncology, Inc | BD Technologies and Innovation (BDTI) | BD Technologies and Innovation | BDTI
Related tests:


BD Onclarity™ HPV Assay receives FDA approval for use with both BD SurePath™ Liquid-based Pap Test and Hologic ThinPrep® Pap Test (BD Bioscience Press Release)
"BD (Becton, Dickinson and Company)...announced U.S. Food and Drug Administration (FDA) market approval for the BD Onclarity™ HPV Assay to be used with the ThinPrep® Pap Test...The inclusion of the ThinPrep® Pap Test improves access to the benefits of the BD human papillomavirus virus (HPV) assay, which is the only FDA-approved assay that tests for an extended set of HPV types individually, and particularly for HPV31, a specific type of HPV that poses a high-risk for causing cervical cancer."
FDA event
BD Onclarity™ HPV Assay
BD, Labcorp collaborate to develop flow cytometry-based companion diagnostics for matching patients with treatments (BD Bioscience Press Release)
"BD (Becton, Dickinson and Company)...announced a collaboration agreement with Labcorp...creating a framework to develop, manufacture, market and commercialize flow cytometry-based companion diagnostics (CDx) intended to match patients with life-changing treatments for cancer and other diseases...The agreement creates a framework for BD and Labcorp Drug Development to collaborate on flow cytometry-based CDx opportunities with pharmaceutical partners. The two companies bring together capabilities that comprise an end-to-end solution for CDx development for the pharmaceutical industry."
Licensing / partnership
BD expands from cancer discovery and diagnosis into post-treatment monitoring with acquisition of Cytognos from Vitro S.A. (BD Bioscience Press Release)
"BD (Becton, Dickinson and Company)...announced it has completed the acquisition of Cytognos, a privately held company headquartered in Salamanca, Spain, specializing in flow cytometry solutions for blood cancer diagnosis, minimal residual disease (MRD) detection and immune monitoring research for blood diseases...Cytognos' key products increase BD's comprehensive portfolio of diagnostic and research solutions for certain types of cancers that use flow cytometry as the primary means of discovery, diagnosis and understanding, including lymphoma, leukemia and multiple myeloma."
FDA approves BD High-Throughput Cor System, HPV screening assay (Genomeweb)
'Becton Dickinson announced Wednesday that it has received US Food and Drug Administration approval for its automated, sample-to-answer, high-throughput BD Cor system along with its Onclarity human papillomavirus extended genotyping assay."
FDA event
BD Onclarity™ HPV Assay